Evidence map›Paper›PMID 35857060›Full record

Observational studyThe Journal of clinical endocrinology and metabolism2022

Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment.

Tomoya Mita, Naoto Katakami, Mitsuyoshi Takahara, Masaru Kawashima, Fumitaka Wada, Hiroki Akiyama, Naru Morita, Yoko Kidani, Toshitaka Yajima, Iichiro Shimomura and 1 more

Abstract readObservational Study
In one paragraph

Observational study in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tomoya MitaDepartment of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Naoto KatakamiDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Mitsuyoshi TakaharaDepartment of Diabetes Care Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Masaru KawashimaOno Pharmaceutical Co., Ltd., Osaka, Japan.
Fumitaka WadaAstraZeneca K.K., Osaka, Japan.
Hiroki AkiyamaAstraZeneca K.K., Osaka, Japan.
Naru MoritaAstraZeneca K.K., Osaka, Japan.
Yoko KidaniAstraZeneca K.K., Osaka, Japan.
Toshitaka YajimaAstraZeneca K.K., Osaka, Japan.ORCID 0000-0001-8409-4937
Iichiro ShimomuraDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hirotaka WatadaDepartment of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0001-5961-1816

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextJ-DISCOVER is a prospective observational cohort study aiming to understand the current management of patients with early-stage type 2 diabetes mellitus (T2DM) in Japan, enrolling patients initiating second-line treatment.

objectiveThe current analysis examined the change in treatment satisfaction during the study period and factors affecting this change among patients in J-DISCOVER.

methodsWe used data from the J-DISCOVER study, in which 1798 patients with T2DM aged ≥ 20 years were enrolled from 142 sites across Japan. Treatment satisfaction was assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ).

resultsThe mean DTSQ treatment satisfaction score increased from 25.9 points at baseline to 27.3 points at 6 months, which was maintained through 36 months. Among the baseline characteristics examined, higher baseline DTSQ treatment satisfaction scores (P < 0.0001), older age (≥ 75 vs < 65 years, P = 0.0096), living alone (P = 0.0356), and type of facility (clinics vs hospitals, P = 0.0044) had a significantly negative impact on the changes in DTSQ treatment satisfaction scores. Improvement in mean glycated hemoglobin (HbA1c) from baseline (7.7%) to 36 months (7.1%) was associated with positive changes in the DTSQ treatment satisfaction score (P = 0.0003).

conclusionChanges in DTSQ treatment satisfaction scores were related to HbA1c improvement, suggesting that the management strategy was appropriately planned for each patient. The results also suggest that the availability of social support for patients with T2DM who are elderly or living alone may be an important factor affecting treatment satisfaction, adherence, and clinical outcomes.

Indexed as

Diabetes Mellitus, Type 2AgedGlycated HemoglobinHumansHypoglycemic AgentsPatient SatisfactionPersonal SatisfactionProspective StudiesGlycated HemoglobinHypoglycemic AgentsDiabetes Treatment Satisfaction QuestionnaireDTSQJ-DISCOVERpatient-reported outcometreatment satisfactiontype 2 diabetes mellitus

Identifiers

PMID35857060
PMCPMC9387712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.